Engineered spider toxin could be the future of anti-venom vaccines

Credit: Elsevier, Vaccine. Kmes Gerholdt/Photolibrary/Getty Images

New engineered spider protein could be the start of a new generation of anti-venom vaccines, potentially saving thousands of lives worldwide. The new protein, created from parts of a toxin from the reaper spider, is described today in the journal Vaccine.

The researchers behind the study, from the Universidade Federal de Minas Gerais in Brazil, say that the engineered protein may be a promising candidate for developing therapeutic serums or vaccines against other venoms.

Reaper spiders, or brown spiders, are a family of species found all over the world that produce harmful venoms. The toxic bite of these spiders causes skin around the bite to die, and can lead to more serious effects like and haemorrhaging. These Loxosceles spiders are most prevalent in Brazil, where they cause almost 7,000 human accidents every year.

The new study describes an engineered protein made of three pieces of a venom from the Loxosceles intermedia spider. The engineered protein is not itself toxic, and gives effective protection against the effects of the pure in animal models.

"In Brazil we see thousands of cases of people being bitten by Loxosceles spiders, and the bites can have very serious side-effects," said Dr. Chávez-Olortegui, corresponding author of the study. "Existing anti-venoms are made of the pure toxins and can be harmful to people who take them. We wanted to develop a new way of protecting people from the effects of these spider bites, without having to suffer from side-effects."

Current approaches to protecting against venom involve giving the venom to animals, and taking the resulting for the . These antibodies enable the to prepare to neutralize venom from bites. Although they are somewhat effective, the production of anti-venoms like these is problematic because animals are required to produce them, and these animals suffer from the effects of the venom.

The new protein is engineered in the lab, without the need for the venomous animals. It is made up of three proteins, so it can protect against more than one kind of toxin at a time. The protein is not harmful to the immunized animal that produces the antibodies. It is also more effective than existing approaches, and easier to produce than preparing crude venom from spiders.

"It's not easy taking venom from a spider, a snake or any other kind of venomous animal," said Chávez-Olortegui. "With our new method, we would be able to engineer the proteins in the lab without having to isolate whole toxins from venom. This makes the whole process much safer."

The researchers tested their new protein on rabbits: all immunized animals showed an immune response similar to the way they respond to the whole toxin. The engineered protein was effective for venom of the L. intermedia and L. gaucho sub-species, which have similar toxins. Immunized rabbits were protected from skin damage at the site of venom injection, and from haemorrhaging.

This engineered protein may be a promising candidate for therapeutic serum development or vaccination in the future.

More information: "Generation and characterization 1 of a recombinant chimeric protein (rCpLi) consisting of B-cell epitopes of a dermonecrotic protein from Loxosceles intermedia spider venom" by T. M. Mendes, D. Oliveira, L. Minozzo, R. Machado de Avila, C. Duarte, C. Dias-Lopes, G. Guimarães, L. Felicori, J. C. Minozzo, C. Chávez-Olortegui, Vaccine, dx.doi.org/10.1016/j.vaccine.2013.03.048

Related Stories

Snake venoms share similar ingredients

Dec 20, 2007

Venoms from different snake families may have many deadly ingredients in common, more than was previously thought. A study published in the online open access journal BMC Molecular Biology has unexpectedly discovered three- ...

Biting back: Snake venom contains toxic clotting factors

Feb 27, 2013

The powerful venom of the saw-scaled viper Echis carinatus contains both anticoagulants and coagulants finds a study published in the launch edition of BioMed Central's open access journal Journal of Venomous Animals and Toxin ...

Scientists tap into Antarctic octopus venom

Jul 21, 2010

(PhysOrg.com) -- Researchers have collected venom from octopuses in Antarctica for the first time, significantly advancing our understanding of the properties of venom as a potential resource for drug-development.

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments